Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Efavirenz versus indinavir among HIV-1 naive patients in Abidjan (Ivory Coast)
Medecine et Maladies Infectieuses, Volume 38, No. 5, Year 2008
Notification
URL copied to clipboard!
Description
Objective: The authors had for aim to compare the therapeutic efficiency and tolerance of 2 NRTI + efavirenz (EFV) versus 2 NRTI + indinavir (IDV) in HIV infected adults in Abidjan. Methods: A retrospective and multicentric study was made on 327 HIV-1 naive patients, 142 in the EFV group and 185 in the IDV group followed in Abidjan from November 1998 to December 2003. The analysis concerned clinical advents (opportunistic infections) and immunovirological parameters (CD4, viral load). Patients received 2 NRTI such as AZT + 3TC or D4T + 3TC combined either with EFV or IDV. The principal judgement criterion was therapeutic failure. We assessed the percentage of patients with undetectable viral load and the frequency of grade 3-4 adverse effects after 24 months of follow-up. Results: Clinical improvement of patients' state and regression of opportunistic infections were identical in the two groups. The average gain of CD4 was superior to 177 in EFV versus + 219 in IDV (p = 0.004). The percentage of patients with undetectable viral load was 66% for EFV versus 59% for IDV (p = 0.04). The frequency of adverse effects was more elevated with EFV than IDV, 39% versus 23% (p = 0.002) initially, but seemed to decrease later. Conclusion: HAART with EFV is at least as efficient as with IDV in terms of reduction of viral load and increased CD4 count and is an excellent low-cost first line treatment. © 2008 Elsevier Masson SAS. All rights reserved.
Authors & Co-Authors
Tanon, Aristophane Koffi
Cote D'ivoire, Abidjan
Centre Hospitalier Universitaire de Treichville
Eholié, Serge Paul
Cote D'ivoire, Abidjan
Centre Hospitalier Universitaire de Treichville
Polneau, Sandrine Vallée
Cote D'ivoire, Abidjan
Université de Cocody-abidjan
Kra, Ouffoué
Cote D'ivoire, Abidjan
Centre Hospitalier Universitaire de Treichville
Ello, Frêdéric Nogbou
Cote D'ivoire, Abidjan
Centre Hospitalier Universitaire de Treichville
Ehui, Eboi
Cote D'ivoire, Abidjan
Centre Hospitalier Universitaire de Treichville
Aoussi, Eba François
Cote D'ivoire, Abidjan
Centre Hospitalier Universitaire de Treichville
Djadji, Ayoman
Cote D'ivoire, Abidjan
Centre Hospitalier Universitaire de Treichville
Kakou, Aka Rigobert
Cote D'ivoire, Abidjan
Centre Hospitalier Universitaire de Treichville
Bissagnéné, Emmanuel
Cote D'ivoire, Abidjan
Centre Hospitalier Universitaire de Treichville
Kadio, Auguste
Cote D'ivoire, Abidjan
Centre Hospitalier Universitaire de Treichville
Statistics
Citations: 11
Authors: 11
Affiliations: 2
Identifiers
Doi:
10.1016/j.medmal.2008.02.004
ISSN:
0399077X
Research Areas
Infectious Diseases
Study Design
Cohort Study
Study Locations
Ivory Coast